Photo by Annie Spratt | Unsplash.com

• Share

PRINT

Most men over 50 will develop an enlarged prostate. Also called benign prostatic hyperplasia (BPH), this bothersome condition makes it hard to urinate and can eventually lead to other problems, such as infections, kidney stones and bladder damage, if left untreated.

Many different BPH therapies are available, including medications and various types of surgery. One of the newer surgical options, called aquablation, trims excess prostate tissues with highly pressurized jets of saline.

Doctors perform aquablation in the operating room while looking at the prostate gland on an ultrasound machine. Patients are put under general anesthesia, so they don’t feel any pain during the procedure.

Aquablation is gaining in popularity — in part because, unlike other more traditional BPH treatments, it can preserve normal ejaculation.

In September, researchers published a study showing that improvements in urinary function from aquablation were still holding up after five years.

Results of data analysis

The study assessed long-term data from two clinical trials. The first, called the WATER trial, launched in 2015 and enrolled 116 men with prostates ranging up to 80 cubic centimeters.

The second trial, WATER II, launched in 2017 and enrolled 101 men with prostates ranging between 80 and 150 cubic centimeters. (Normal prostates range from 25 to 30 cubic centimeters in size.) Enrolled patients had a median age of 66 in the WATER study and 68 in WATER II.

Both clinical trials used the so-called International Prostate Symptom Score (IPSS) to measure treatment-related improvements in urinary functioning and quality of life. Calculated based on how patients rate their symptoms on a standardized questionnaire, IPSS scores greater than 19 indicate severe symptoms.

When they first enrolled in the trials, men in the WATER and WATER II studies reported average IPSS scores of 22.9 and 23.3 respectively. Five years later, the average respective scores were much lower: 7.0 and 6.8. Only 1% of men were taking BPH medications after five years, and fewer than 5% had been surgically re-treated.

A word of caution

Aquablation can result in extended bleeding, cautions Dr. Heidi Rayala, an assistant professor of urology at Harvard Medical School and a member of the Harvard Medical School Guide to Prostate Diseases advisory board. That’s because unlike other types of surgery for BPH, including prostate enucleation, aquablation doesn’t cauterize tissues with heat.

“I tell my patients to expect some blood in the urine for about four to six weeks after the procedure,” Dr. Rayala said.

Moreover, aquablation may be unsuitable for some men who take blood thinners to prevent blood from clotting, according to Dr. Rayala. Appropriate candidates for the surgery must be able to “safely discontinue anticoagulant medications during post-operative healing, given the bleeding risk,” Dr. Rayala said.

Still, aquablation is an excellent option for most men, Dr. Rayala said, especially those with medium to large prostates “who want a durable solution with a lower risk of sexual side effects.”

Larger studies are necessary, said Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of the Harvard Medical School Guide to Prostate Diseases.

“These early results are encouraging, but limited by a relatively small number of patients,” Garnick said. “Further evidence with a significantly larger number of patients and longer follow-up will help to support this new method of reducing prostate tissue as an important treatment option.”

Charlie Schmidt is editor of the Harvard Medical School Annual Report on Prostate Diseases.

© 2025 Harvard University. Distributed by Tribune Content Agency, LLC.